News | Prostate Cancer | July 22, 2025

An accepted manuscript published in the American Roentgen Ray Society’s American Journal of Roentgenology  looks at how artificial intelligence can improve diagnostic consistency and reduce false-positives in prostate cancer detection.

Lesion Identification by AI and Histopathologic Annotation

July 16, 2025 — Artificial intelligence can improve diagnostic consistency and reduce false-positives in prostate cancer detection, according to an accepted manuscript published in the American Roentgen Ray Society’s American Journal of Roentgenology (AJR).

Noting enhanced clinical utility for radiologists, “AI may enhance consistency and reduce false-positives in prostate biparametric MRI (bpMRI) interpretation,” clarified AJR corresponding author Baris Turkbey, MD, from the National Cancer Institute and National Institutes of Health in Bethesda, MD. “Further optimization is required to improve sensitivity without compromising specificity.”

Turkbey et al.’s multireader, multicenter study used a balanced incomplete block design for MRI randomization. Six radiologists of varying experience interpreted bpMRI scans with and without AI assistance in alternating sessions. The reference standard for lesion-level detection for cases was whole-mount pathology after radical prostatectomy; for control patients, negative 12-core systematic biopsies. In all, 180 patients (120 case group, 60 control group) who underwent mpMRI and prostate biopsy or radical prostatectomy between January 2013 and December 2022 were included. The AJR authors then assessed lesion-level sensitivity, PPV, patient-level AUC for clinically significant prostate cancer and prostate cancer detection, and interreader agreement in lesion-level PI-RADS scores and size measurements.

Ultimately, AI-assisted bpMRI interpretation improved lesion-level PPV for prostate cancer (PI-RADS ≥ 3: 80.9% vs. 69.4%, p < .001) and significantly enhanced interreader agreement for PI-RADS scoring (κ = 0.748 vs. 0.336, p < .001) but slightly reduced sensitivity.

A supplement to this AJR manuscript is available online.

 

Lesion Identification by AI and Histopathologic Annotation
77-year-old man with serum PSA of 17.8 ng/mL. A) T2-weighted (T2W) MRI shows hypointensity in the left posterolateral peripheral zone. B) AI segmentation map overlaid on T2W image shows predicted prostate segmentation boundary in blue and PCa-suspicious lesion prediction segmentation in red. C) Ground truth histopathology slide registered to MR image shows annotated lesion segmented in red. D) Histopathologic annotation of whole mount prostate tissue after radical prostatectomy. This patient was found to have Gleason 4+3 disease in the region marked in blue. Yellow outlines represent cribriform architecture, red represents regions of Gleason 3, and light blue represents areas of lymphovascular invasion.

 


Related Content

News | Artificial Intelligence

July 22, 2025 — GE HealthCare has topped a U.S. Food and Drug Administration (FDA) list of AI-enabled medical device ...

Time July 23, 2025
arrow
Feature

A new study published in JCO Clinical Cancer Informatics tackles a critical challenge in cancer diagnostics: ensuring ...

Time July 01, 2025
arrow
News | Prostate Cancer

June 26, 2025 – Quibim, a global provider of quantitative medical imaging solutions, has launched AI-QUAL, a new feature ...

Time June 26, 2025
arrow
News | Pediatric Imaging

April 10, 2025 — Cincinnati Children’s and GE HealthCare will form a strategic research program focused on driving ...

Time April 10, 2025
arrow
News | Radiology Imaging

Jan. 15, 2025 — University of California, San Francisco (UCSF) Department of Radiology & Biomedical Imaging and GE ...

Time January 27, 2025
arrow
News | Contrast Media

Jan. 10, 2025 – Bayer has announced positive topline results of the Phase III QUANTI studies evaluating the efficacy and ...

Time January 14, 2025
arrow
News | Women's Health

Aug. 19, 2024 — GE HealthCare recently announced a collaboration with the University of California San Diego School of ...

Time August 29, 2024
arrow
News | Radiology Business

July 25, 2024 — Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and ...

Time July 25, 2024
arrow
News | Radiopharmaceuticals and Tracers

July 24, 2024 — Telix Pharmaceuticals Limited announced that the United States (U.S.) Food and Drug Administration (FDA) ...

Time July 24, 2024
arrow
News | RSNA

July 23, 2024 — Professional registration is open for RSNA 2024, the world’s largest radiology forum. This year’s theme ...

Time July 23, 2024
arrow
Subscribe Now